Daraxonrasib for Pancreatic Cancer: Resistance Mechanisms and Combination Strategies
Daraxonrasib, a RAS(ON) multi-selective inhibitor evaluated in phase 1/2 clinical trials for pancreatic cancer, faces hurdles with acquired drug resistance. Published in Nature Medicine on August 11, 2026, circulating tumor … Read More